Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1983 2
1984 1
1985 3
1986 3
1987 12
1988 66
1989 115
1990 211
1991 460
1992 821
1993 878
1994 939
1995 1049
1996 1028
1997 914
1998 989
1999 965
2000 1012
2001 1070
2002 1062
2003 1175
2004 1244
2005 1261
2006 1238
2007 1318
2008 1161
2009 1187
2010 1328
2011 1471
2012 1379
2013 1382
2014 1254
2015 1149
2016 833
2017 672
2018 503
2019 200
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

28,447 results
Results by year
Filters applied: . Clear all
Page 1
Role of MxB in Alpha Interferon-Mediated Inhibition of HIV-1 Infection.
Xu B, et al. J Virol 2018. PMID 29925663 Free PMC article.
Interestingly, a CRISPR/Cas9 knockout screen of alpha interferon-stimulated genes in U87-MG cells revealed that the genes for interferon-induced transmembrane protein 2 (IFITM2) and IFITM3 inhibited VSV G-pseudotyped HIV-1 much more strongly than the rest of the genes tested, including the gene for MxB. Therefore, our results demonstrate the importance of MxB in alpha interferon-mediated inhibition of HIV-1 infection, which, however, can be underestimated if infection is performed with VSV G protein-pseudotyped HIV-1, due to the high sensitivity of VSV G-mediated infection to inhibition by IFITM proteins.IMPORTANCE The results of this study reconcile the controversial reports regarding the anti-HIV-1 function of alpha interferon-induced MxB protein. ...
Interestingly, a CRISPR/Cas9 knockout screen of alpha interferon-stimulated genes in U87-MG cells revealed that the genes for …
Chronic Hepatitis B Infection: A Review
Tang LSY, et al. JAMA 2018 - Review. PMID 29715359
OBSERVATIONS: Pegylated interferon and nucleos(t)ide analogues (lamivudine, adefovir, entecavir, tenofovir disoproxil, and tenofovir alafenamide) suppress HBV DNA replication and improve liver inflammation and fibrosis. ...The cure (defined as hepatitis B surface antigen loss with undetectable HBV DNA) rates after treatment remain low (3%-7% with pegylated interferon and 1%-12% with nucleos[t]ide analogue therapy). ...
OBSERVATIONS: Pegylated interferon and nucleos(t)ide analogues (lamivudine, adefovir, entecavir, tenofovir disoproxil, and tenofovir …
Systemic treatments for metastatic cutaneous melanoma
Pasquali S, et al. Cochrane Database Syst Rev 2018 - Review. PMID 29405038 Free PMC article.
Interventions were categorised into five groups: conventional chemotherapy (including single agent and polychemotherapy), biochemotherapy (combining chemotherapy with cytokines such as interleukin-2 and interferon-alpha), immune checkpoint inhibitors (such as anti-CTLA4 and anti-PD1 monoclonal antibodies), small-molecule targeted drugs used for melanomas with specific gene changes (such as BRAF inhibitors and MEK inhibitors), and other agents (such as anti-angiogenic drugs). ...Compared with chemotherapy, biochemotherapy (in this case, chemotherapy combined with both interferon-alpha and interleukin-2) and BRAF inhibitors improved progression-free survival; BRAF inhibitors (for BRAF-mutated melanoma) and anti-PD1 monoclonal antibodies improved overall survival. ...
Interventions were categorised into five groups: conventional chemotherapy (including single agent and polychemotherapy), biochemotherapy (c …
Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma.
Ma H, et al. Br J Cancer 2019. PMID 30555157 Free PMC article.
Whether interferon alpha (IFNα) can suppress immune and cancer cells and its involved mechanism still remain largely elusive. METHODS: We examine the expression of interferon alpha/beta receptor-1 (IFNAR1), CD8, CD56 and programmed death ligand 1 (PDL1) in head and neck squamous cell carcinomas (HNSCC). ...
Whether interferon alpha (IFNα) can suppress immune and cancer cells and its involved mechanism still remain largely elusive. …
Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer.
Provance OK and Lewis-Wambi J. Breast Cancer Res 2019 - Review. PMID 31060575 Free PMC article.
Recently, the type I interferon, specifically the interferon alpha signature, has been identified as a pathway upregulated in IBC but few studies have addressed its role. ...The mechanisms promoting the increase in interferon alpha expression and the role interferon alpha plays in IBC remain speculative. ...
Recently, the type I interferon, specifically the interferon alpha signature, has been identified as a pathway upregula …
Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC and Holmström MO. Semin Immunopathol 2019 - Review. PMID 30203226 Free PMC article.
The first clinical trials of the safety and efficacy of interferon-alpha2 (IFN-alpha2) were performed about 30 years ago. Since then, several single-arm studies have convincingly demonstrated that IFN-alpha2 is a highly potent anti-cancer agent in several cancer types but unfortunately not being explored sufficiently due to a high toxicity profile when using non-pegylated IFN-alpha2 or high dosages or due to competitive drugs, that for clinicians at first glance might look more attractive. ...Interferon-alpha2 being the cornerstone treatment in MPNs and having the potential of inducing minimal residual disease (MRD) with normalization of the bone marrow and low-JAK2V617F allele burden, we believe that combination therapy with ruxolitinib may be even more efficacious and hopefully revert disease progression in many more patients to enter the path towards MRD. ...
The first clinical trials of the safety and efficacy of interferon-alpha2 (IFN-alpha2) were performed about 30 years ago. Since then, …
Cytokines in clinical cancer immunotherapy
Berraondo P, et al. Br J Cancer 2019 - Review. PMID 30413827 Free PMC article.
Based on the discovery of the potent anti-tumour activities of several pro-inflammatory cytokines in animal models, clinical research led to the approval of recombinant interferon-alpha and interleukin-2 for the treatment of several malignancies, even if efficacy was only modest. ...
Based on the discovery of the potent anti-tumour activities of several pro-inflammatory cytokines in animal models, clinical research led to …
Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
Deterding K and Wedemeyer H. AIDS Rev 2019 - Review. PMID 31532397
The current treatment options are limited as only pegylated interferon-alpha (PEG-IFNa) has efficacy against HDV. However, treatment response is still unsatisfactory with 25-40% HDV RNA suppression after 1-2 years. ...
The current treatment options are limited as only pegylated interferon-alpha (PEG-IFNa) has efficacy against HDV. However, tre …
Interferon-alpha in the treatment of myeloproliferative diseases.
Kissová J. Vnitr Lek 2019. PMID 31906676
Interferon α (IFNα) has been recognized as a substance for the treatment of MPN for more than 30 years, but its widespread use has been limited by higher frequency of short-term adverse reactions compared to conventional treatment and until recently, by its off-label indication in BCR/ABL negative MPNs. ...
Interferon α (IFNα) has been recognized as a substance for the treatment of MPN for more than 30 years, but its wid
28,447 results
Jump to page
Feedback